UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549

FORM 10-Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2000

OR

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to ___________

Commission File Number 0-23837

SurModics, Inc.
(Exact name of registrant as specified in its Charter)

MINNESOTA	41-1356149
(State of incorporation)	(I.R.S. Employer Identification No.)

9924 West 74th Street
Eden Prairie, Minnesota 55344
(Address of principal executive offices)

Registrant's telephone number, including area code: (612) 829-2700

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes X No __

The number of shares of the registrant's Common Stock, $.05 par value per share, outstanding as of April 30, 2000 was 7,816,820.

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

SURMODICS, INC.
Condensed Balance Sheets
(In thousands, except share data)

ASSETS	March 31, 2000 (Unaudited)	September 30, 1999
CURRENT ASSETS:		
Cash & cash equivalents	$2,640	$1,975
Short-term investments	10,415	3,947
Accounts receivable, net	1,360	1,433
Inventories	511	459
Prepaids and other	618	260
Total current assets	15,544	8,074
PROPERTY AND EQUIPMENT, net	6,879	5,275
LONG-TERM INVESTMENTS	9,246	15,917
DEFERRED TAX ASSETS	1,374	2,465
OTHER ASSETS, net	216	227
	$33,259	$31,958
LIABILITIES AND STOCKHOLDERS' EQUITY		
CURRENT LIABILITIES:		
Accounts payable	$641	$710
Accrued liabilities	1,021	1,261
Deferred revenues	160	268

Total liabilities	1,822	2,239
COMMITMENTS AND CONTINGENCIES		
STOCKHOLDERS' EQUITY:		
Series A Preferred stock- $.05 par value, 150,000 shares authorized; no shares issued or outstanding	--	--
Common stock- $.05 par value, 45,000,000 shares authorized; 7,802,805 and 7,701,921 shares issued and outstanding	390	385
Additional paid-in capital	31,904	32,009
Unearned compensation	(216)	(267)
Stock purchase notes receivable	(38)	(58)
Accumulated other comprehensive loss	(287)	(187)
Accumulated deficit	(316)	(2,163)
Total stockholders' equity	31,437	29,719
	$33,259	$31,958

The accompanying notes are an integral part of these condensed balance sheets.

SURMODICS, INC.
Condensed Statements of Income
(In thousands, except per share data)
(Unaudited)

	Three Months Ended March 31,		Six Months Ended March 31,	
	2000	1999	2000	1999
REVENUES:				
Royalties	$2,503	$1,530	$4,853	$2,836
License fees	160	60	260	325
Product sales	1,188	1,160	2,422	1,790
Research and development	590	558	1,055	996
Total revenues	4,441	3,308	8,590	5,947
OPERATING COSTS AND EXPENSES:				
Product	467	397	862	679
Research and development	1,776	1,213	3,384	2,379
Sales and marketing	354	437	732	835
General and administrative	693	670	1,255	1,198
Total operating costs and expenses	3,290	2,717	6,233	5,091
INCOME FROM OPERATIONS	1,151	591	2,357	856
OTHER INCOME:				
Investment income, net	307	260	600	530
Gain (loss) on sale of investments	(11)	(3)	(10)	95
Other income, net	296	257	590	625
INCOME BEFORE PROVISION FOR INCOME TAXES	1,447	848	2,947	1,481
INCOME TAX BENEFIT (PROVISION)	(543)	257	(1,100)	549
NET INCOME	$904	$1,105	$1,847	$2,030
NET INCOME PER SHARE:				
Basic	$0.12	$0.15	$0.24	$0.28
Diluted	$0.11	$0.14	$0.22	$0.26
WEIGHTED AVERAGE SHARES OUTSTANDING:				
Basic weighted average common shares outstanding	7,782	7,270	7,750	7,250
Dilutive effect of outstanding stock options	563	722	557	670
Diluted weighted average common shares outstanding	8,345	7,992	8,307	7,920

The accompanying notes are an integral part of these condensed financial statements.

SURMODICS, INC.
Condensed Statements of Cash Flows
(In thousands)
(Unaudited)

	Six Months Ended March 31, 2000	Six Months Ended March 31, 1999
OPERATING ACTIVITIES:		
Net income	$1,847	$2,030
Adjustments to reconcile net income to net cash provided by operating activities-		
Depreciation and amortization	485	346
Amortization of unearned compensation, net	43	30
Change in deferred rent	--	(12)
Change in deferred tax	1,091	(552)
Change in assets and liabilities:		
Accounts receivable	73	(371)
Inventories	(52)	(52)
Prepaids and other	(358)	(13)
Accounts payable and accrued liabilities	(309)	(434)
Deferred revenues	(108)	(66)
Net cash provided by operating activities	2,712	906
INVESTING ACTIVITIES:		
Purchases of property and equipment, net	(2,078)	(758)
Purchases of available-for-sale investments	(13,626)	(15,434)
Sales/maturities of available-for-sale investments	13,729	14,631
Repayment of stock purchase notes receivable	20	68
Net cash used in investing activities	(1,955)	(1,493)
FINANCING ACTIVITIES:		
Issuance of common stock, net	(92)	408
Net increase (decrease) in cash and cash equivalents	665	(179)
CASH AND CASH EQUIVALENTS:		
Beginning of period	1,975	1,344
End of period	$2,640	$1,165

The accompanying notes are an integral part of
these condensed financial statements.

SURMODICS, INC.
Notes to Condensed Financial Statements
(Unaudited)

(1) Basis of Presentation:

In the opinion of management, the accompanying unaudited condensed financial statements have been prepared in accordance with generally accepted accounting principles and reflect all adjustments, consisting solely of normal recurring adjustments, needed to fairly present the financial results for these interim periods. These financial statements include some amounts that are based on management's best estimates and judgments. These estimates may be adjusted as more information becomes available, and any adjustment could be significant. The results of operations for the three months and six months ended March 31, 2000 are not necessarily indicative of the results that may be expected for the entire fiscal year.

According to the rules and regulations of the Securities and Exchange Commission, the Company has omitted footnote disclosures that would substantially duplicate the disclosures contained in the audited financial statements of the Company. Read together with the disclosures below, management believes the interim financial statements are presented fairly. However, these unaudited condensed financial statements should be read together with the financial statements for the year ended September 30, 1999 and footnotes thereto included in the Company's form 10-KSB as filed with the Securities and Exchange Commission.

(2) New Accounting Pronouncements

The Financial Accounting Standards Board (FASB) issued Statement of Financial Accounting Standards (SFAS) No. 133, "Accounting for Derivative Instruments and Hedging Activities," and SFAS No. 137, "Deferral of the Effective Date of SFAS No. 133," which establishes accounting and reporting standards requiring that every derivative instrument (including certain derivative instruments embedded in other contracts) be recorded in the balance sheet as either an asset or liability measured at its fair value. If certain conditions are met, a derivative may qualify for hedge accounting. Based on current operations, the Company anticipates that the adoption of SFAS No. 133 at the beginning of fiscal 2001 will not have a significant impact on its results of operations.

(3) Comprehensive Income

The components of comprehensive income for the three-month and six-month periods are as follows:

	Three months ended March 31,		Six months ended March 31,	
(dollars in thousands)	2000	1999	2000	1999
Net income	$904	$1,105	$1,847	$2,030
Other comprehensive income:				
Change in unrealized loss on available-for-sale securities	(4)	(117)	(100)	(312)
Total comprehensive income	$900	$988	$1,747	$1,718

(4) Operating Segments

(dollars in thousands)	Licensing	Manufacturing	Research & Development	Corporate	Consolidated
Six Months Ended March 31, 2000					
Revenues:					
PhotoLink	$3,475	$1,106	$668	$ -	$5,249
Diagnostic	1,638	-	-	-	1,638
Stabilization & other	-	1,316	-	-	1,316
Government	-	-	387	-	387
Total Revenues	5,113	2,422	1,055	-	8,590
Expenses	-	862	3,384	1,987	6,233
Operating income (loss)	5,113	1,560	(2,329)	(1,987)	2,357
Other income				590	590
Income tax provision				(1,100)	(1,100)
Net income					$1,847
Six Months Ended March 31, 1999					
Revenues:					
PhotoLink	$1,834	$775	$492	$ -	$3,101
Diagnostic	1,327	-	-	-	1,327
Stabilization & other	-	1,015	-	-	1,015
Government	-	-	504	-	504
Total Revenues	3,161	1,790	996	-	5,947
Expenses	-	679	2,379	2,033	5,091
Operating income (loss)	3,161	1,111	(1,383)	(2,033)	856
Other income				625	625
Income tax benefit				549	549
Net income					$2,030

(5) 1999 Employee Stock Purchase Plan

On November 15, 1999 the Board of Directors adopted, and on January 24, 2000 shareholders approved, the Company's 1999 Employee Stock Purchase Plan (the "Stock Purchase Plan"). The Stock Purchase Plan permits all full-time and part-time employees (including officers) of the Company to purchase stock of the Company. The Stock Purchase Plan does not allow an employee to purchase stock through the Stock Purchase Plan if immediately after the grant of an option, he or she would own stock representing 5% or more of the total combined voting power or value of all classes of the stock of the Company. The Stock Purchase Plan will terminate on February 28, 2010, unless the Board of Directors extends the term of the Plan.

(6) Stockholders' Equity

On January 24, 2000 shareholders approved an amendment to the Articles of Incorporation to eliminate all references in the Articles to a class of Convertible Preferred Stock, shares of which were automatically converted as part of the Company's initial public offering in 1998.

Additionally, the Amendment increased the total number of authorized shares of the Company to 50,000,000 consisting of 45,000,000 shares of Common Stock, $0.05 par value per share, 150,000 of Series A Preferred Stock, $.05 par value per share, and 4,850,000 undesignated shares.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

General

SurModics is a leading provider of surface modification solutions to medical device manufacturers. The Company's revenues are derived from four primary sources: fees from licensing its patented technology to customers; royalties received from licensees; the sale of photoreactive chemical compounds to licensees and stabilization products to the diagnostics industry; and research and development fees generated on projects for commercial customers and pursuant to government grants.

Results of Operations

Three Months Ended March 31, 2000 and 1999

Revenues. The Company's revenues were $4.4 million for the second quarter of fiscal 2000, an increase of $1.1 million, or 34%, over the same period of fiscal 1999. The revenue components were as follows (in thousands):

	2000	1999	$ Increase (Decrease)	% Increase (Decrease)
PhotoLink revenue:				
Royalties	$1,571	$814	$757	93%
License fees	160	60	100	167%
Reagent chemical sales	501	530	(29)	(5%)
Commercial development	396	283	113	40%
Total PhotoLink revenue	2,628	1,687	941	56%
Other revenue:				
Diagnostic royalties	933	716	217	30%
Stabilization & other products	686	630	56	9%
Government research	194	275	(81)	(29%)
Total revenues	$4,441	$3,308	$1,133	34%

Second quarter revenue growth of 34% was primarily a result of a 56% increase in PhotoLink-related revenue. The 93% growth in PhotoLink royalties was due mostly to increased sales of coated products sold by the Company's licensees. During the quarter, approximately 82% of the PhotoLink royalties received were earned royalties based on the clients' sale of coated products. The remaining royalties were minimum payments made to SurModics prior to a medical device reaching the market. There were no additional license agreements signed during the second quarter. The $160,000 of license revenue was due to progress payments on PhotoLink license agreements signed in previous periods. The Company has license agreements with 46 companies covering over 100 different products.

The 5% decrease in reagent chemical sales (those chemicals used by licensees in the PhotoLink coating process) was partially due to the reduction of sales to a single client as a result of collaborative efforts to improve processing efficiencies. While sales to this client continued to represent more than half of the reagents sold during the quarter, reagent sales to all other customers increased 22% over the same period last year.

Commercial development revenue increased 40% due mostly to a large development project for a single client. While this project is continuing, the level of effort is expected to revert back to a more normal level. Therefore, commercial development revenue may decrease in the third quarter. The 30%

increase in diagnostic royalty revenue contributed to the majority of revenue growth outside of PhotoLink. These royalties were impacted by a one-time spurt in sales. It is anticipated that the diagnostic royalties will be lower than historical levels over the next several quarters until certain manufacturing issues of a licensee are resolved.

Product costs. The Company's product costs were $467,000 for the second quarter of fiscal 2000, an increase of $70,000, or 18%, over the same period of fiscal 1999. Overall product margins decreased to 61% in the second quarter of fiscal 2000 from 66% in the same period of fiscal 1999. The margin decline was primarily due to the scrapping of several production lots that failed to meet quality standards in the second quarter. It is expected that margins will return to recent levels in the third quarter.

Research and development expenses. Research and development expenses were $1.8 million for the second quarter of fiscal 2000, an increase of $563,000, or 46%, over the same period of fiscal 1999. The change was primarily due to compensation and benefits associated with technical personnel added by the Company over the last year, increased patent and legal fees, and supplies cost to equip the newly completed laboratory space.

Sales and marketing expenses. Sales and marketing expenses were $354,000 for the second quarter of fiscal 2000, an $83,000 or 19% decrease from the same period of fiscal 1999. Increased promotional expenses were more than offset by decreased compensation and benefit costs due to open positions. The company is currently attempting to fill these open positions.

General and administrative expenses. General and administrative expenses were $693,000 for the second quarter of fiscal 2000, an increase of $23,000, or 3%, over the same period of fiscal 1999. The increase was the result of higher compensation and benefit costs and offset by lower outside consulting costs.

Income from operations. The Company's income from operations was $1.2 million for the second quarter of fiscal 2000, an increase of $560,000, or 95%, over the same period of fiscal 1999.

Other income, net. The Company's other income was $296,000 for the second quarter of fiscal 2000, an increase of $39,000, or 15%, over the same period of fiscal 1999. The increase is due to higher investment balances in the current period.

Income tax expense. The Company's income tax provision was $543,000 for the second quarter of fiscal 2000 versus a $257,000 income tax benefit recorded in the same period of fiscal 1999. Net income for the second quarter of fiscal 1999 included the reversal of income tax valuation reserves of approximately $571,000 reducing the Company's tax provision at statutory rates to a net credit of $257,000. Excluding the effect of the reversal of income tax valuation reserves, the Company's net income and diluted income per share would have been as follows on a proforma basis:

	Proforma Three Months Ended March 31, 2000	1999
Net income before provision for income taxes	$1,447,000	$848,000
Income tax provision	(543,000)	(314,000)
Net income	$ 904,000	$534,000
Diluted net income per share	$0.11	$0.07

Other comprehensive loss. The Company's other comprehensive loss was $4,000 for the second quarter of fiscal 2000. This loss was due to a reduction in the market value of the Company's long-term investments available-for-sale due to increases in interest rates. As of March 31, 2000, the Company had a net $287,000 unrealized loss related to those investments.

Six Months Ended March 31, 2000 and 1999

Revenues. The Company's revenues were $8.6 million for the first six months of fiscal 2000, an increase of $2.6 million, or 44%, over the same period of fiscal 1999. The revenue components were as follows (in thousands):

	2000	1999	$ Increase (Decrease)	% Increase (Decrease)
PhotoLink revenue:				
Royalties	$3,215	$1,509	$1,706	113%
License fees	260	325	(65)	(20%)
Reagent chemical sales	1,106	775	331	43%
Commercial development	668	492	176	36%
Total PhotoLink revenue	5,249	3,101	2,148	69%
Other revenue:				
Diagnostic royalties	1,638	1,327	311	23%
Stabilization & other products	1,316	1,015	301	30%
Government research	387	504	(117)	(23%)
Total revenues	$8,590	$5,947	$2,643	44%

The overall revenue growth of 44% for the first six months was distributed across several operating segments but resulted primarily from a 69% increase in PhotoLink-related revenue. The 113% growth in PhotoLink royalties was due primarily to increased sales of coated products sold by the Company's licensees. In addition, the first quarter royalties included a one-time royalty payment of $225,000 from a client as the result of a license renegotiation. During the period, approximately 84% of the PhotoLink royalties received were earned royalties based on the clients' sale of coated products. The remaining royalties were minimum payments made to SurModics prior to a medical device reaching the market.

The 43% increase in reagent chemical sales was due to growing production of PhotoLink-coated devices by SurModics' clients. SurModics signed five new PhotoLink license agreements during the first six months. The fees from these agreements, in addition to progress payments made on previously executed license agreements resulted in $260,000, a 20% decrease from the $325,000 recorded on the seven license agreements signed in the same period last year. Stabilization and other product sales increased 30% from the same period in fiscal 1999. This rate of growth is not expected to continue since stabilization sales have leveled out over the last few quarters.

Product costs. The Company's product costs were $862,000 for the first six months of fiscal 2000, an increase of $183,000, or 27%, over the same period of fiscal 1999. Overall product margins increased to 64% in the first six months of fiscal 2000 from 62% in the same period of fiscal 1999. The continued margin improvement was the result of efficiencies achieved in manufacturing reagent chemicals and stabilization products based on increased production volumes.

Research and development expenses. Research and development expenses were $3.4 million for the first six months of fiscal 2000, an increase of $1.0 million, or 42%, over the same period of fiscal 1999. The change was primarily due to compensation and benefits associated with technical personnel added by the Company over the last year, increased patent and legal fees, and supplies cost to equip the newly completed laboratory space.

Sales and marketing expenses. Sales and marketing expenses were $732,000 for the first six months of fiscal 2000, a $103,000 or 12% decrease from the same period of fiscal 1999. Increased promotional expenses were more than offset by decreased compensation and benefit costs due to open positions.

General and administrative expenses. General and administrative expenses were $1.3 million for the first half of fiscal 2000, an increase of $57,000, or 5%, over the same period of fiscal 1999. The increase was primarily the result of higher compensation and benefit costs.

Income from operations. The Company's income from operations was $2.4 million for the first six months of fiscal 2000, an increase of $1.5 million, or 175%, over the same period of fiscal 1999.

Other income, net. The Company's other income was $590,000 for the first half of fiscal 2000, a decrease of $35,000, or 6%, over the same period of fiscal 1999. An increase in investment income in the current period was offset by a decrease in realized gains on the sale of investments. The first half of fiscal 1999 included a $95,000 realized gain from the sale of investments.

Income tax expense. The Company's income tax provision was $1.1 million for the first six months of fiscal 2000 versus a $549,000 income tax benefit recorded in the same period of fiscal 1999. Net income for the first half of fiscal 1999 included the reversal of income tax valuation reserves of approximately $1,062,000 reducing the Company's tax provision at statutory rates to a net credit of $549,000. Excluding the effect of the reversal of income tax valuation reserves, the Company's net income and diluted income per share would have been as follows on a proforma basis:

	Proforma Six Months Ended March 31,	
	2000	1999
Net income before provision for income taxes	$2,947,000	$1,481,000
Income tax provision	(1,100,000)	(513,000)
Net income	$1,847,000	$ 968,000
Diluted net income per share	$0.22	$0.12

Other comprehensive loss. The Company's other comprehensive loss was $100,000 for the first six months of fiscal 2000. This loss was due to a reduction in the market value of the Company's long-term investments available-for-sale due to increases in interest rates. As of March 31, 1999, the Company had a net $287,000 unrealized loss related to those investments.

Liquidity and Capital Resources

As of March 31, 2000, the Company had working capital of $13.7 million and cash, cash equivalents and investments totaling $22.3 million. The Company's investments principally consist of U.S. government agency obligations and investment grade, interest-bearing corporate debt securities with varying maturity dates, the majority of which are one year or less. The Company generated positive cash flows from operating activities of $2.7 million in the first six months, which was an increase of 199% for the same period of last year, primarily due to the change in the deferred tax asset as described above. Approximately $2.0 million of cash was used for investing activities during the first six months compared to $1.5 million last year. The significant change in investing activities between years was the construction of additional laboratory and office space that was completed in December 1999. The total cost of the additional space was approximately $1.0 million. Finally, a net $92,000 was utilized in financing activities due to the exercise of stock options, net of stock swaps during the first six months of the year.

As of March 31, 2000, the Company had no debt, nor did it have any credit agreements. The Company believes that its existing capital resources will be adequate to fund the Company's operations into the foreseeable future.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The Company maintains an investment portfolio in accordance with its investment policy. The primary objectives of the Company's investment policy are to preserve principal, maintain proper liquidity to meet operating needs and maximize yields. The Company's investment policy requires investments with high-credit-quality issuers and limits the amount of credit exposure to any one issuer.

The Company's investments principally consist of U.S. government and government agency obligations and investment grade, interest-bearing corporate debt securities with varying maturity dates, the majority of which are three years or less. All of the Company's cash equivalents and marketable securities are classified as available-for-sale securities.

The securities held in the Company's investment portfolio are subject to interest rate risk. Changes in interest rates affect the fair market value of the available-for-sale securities. The Company has determined that a hypothetical ten percent increase in interest rates would result in an approximate $150,000 decrease in the fair value of the Company's available-for-sale securities as of March 31, 2000, but would have no material impact on the results of operations or cash flows. SurModics does not use derivative instruments in its investment portfolio.

Forward Looking Statements

The statements contained in this quarterly report relating to future revenue growth and expense levels are based on current expectations and involve a number of risks and uncertainties. These statements are forward looking and are made pursuant to the safe harbor provisions of the Private Securities Reform Act of 1995. The following factors could cause royalty revenue to materially and adversely differ from that anticipated: the ability of the Company's licensees to successfully gain regulatory approval for, market and sell products incorporating the Company's technology; the amount and timing of resources devoted by the Company's licensees to market and sell products incorporating the Company's technology; the Company's ability to attract new licensees and to enter into agreements for additional applications with existing licensees; the Company's ability to maintain a competitive position in the development of technologies and products in its areas of focus; and business and general economic conditions.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

None.

Item 2. Changes in Securities and Use of Proceeds.

Use of Proceeds for the period ending March 31, 1999.

(1)	Effective Date:	March 3, 1998
	SEC File Number:	333-43217
(2)	Offering Date:	March 3, 1998
(4)(i)	The offering has terminated; all securities registered were sold.	
(4)(ii)	Managing Underwriter:	John G. Kinnard and Company, Incorporated
(4)(iii)	Title of Securities:	Common Stock
(4)(iv)	Amount Registered:	2,300,000
	Aggregate Offering Price:	$17,250,000
	Amount Sold:	2,300,000
	Aggregate Offering Price Sold:	$17,250,000
(4)(v)	Underwriting Discount and Commissions	$ 1,293,750
	Other Expenses	$ 435,148
	Total Expenses	$ 1,728,898
	All the above items represented direct or indirect payments to others.	
(4)(vi)	Net Offering Proceeds	$15,521,102
(4)(vii)	Use of Net Offering Proceeds:	
	Research and development	$ 1,772,000
	Sales and marketing	$ 1,173,000
	Property and equipment upgrades	$ 7,180,000
	Patent protection	$ 143,000
	Working capital and general corporate purposes	$ 852,000
	Administration	$ 124,000
	Money market funds	$ 4,277,102
	All the above items represented direct or indirect payments to others.	

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Submission of Matters to a Vote of Security Holders.

None.

Item 5. Other Information.

None.

Item 6. Exhibits and Reports on Form 8-K.

(a) Exhibits - 27 Financial Data Schedule

(b) Reports on Form 8-K - None

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SurModics, Inc.

May 15, 2000

By: /s/ Stephen C. Hathaway
Stephen C. Hathaway
Vice President & CFO
(Principal Financial Officer)

Exhibit Index

Exhibit Number	Description
27	Financial Data Schedule

5
1,000
U.S. Dollars

6-MOS
SEP-30-2000
OCT-01-1999
MAR-31-2000
1
2,640
10,415
1,400
40
511
15,544
11,388
4,509
33,259
1,822
0
0
0
390
31,047
33,259
2,422
8,590
862
6,233
0
0
0
2,947
1,100
1,847
0
0
0
1,847
.24
.22